Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834

Q1 FY26 results · Apr–Jun 2025

Camlin Fine Sciences reported revenue from operations of ₹423.55 crore (up 7.0% from Q1 FY25) and net loss of ₹10.68 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	423.55	395.85	+7.0%	437.46	−3.2%
Other income	8.56	1.87	+358.5%	9.59	−10.7%
Total income	432.12	397.72	+8.6%	447.06	−3.3%
Profit before share of associates & JVs and tax	(5.15)	(23.48)	Loss narrowed	28.91	Turned loss
Share of profit/(loss) of associates & JVs	0.89	0.00		1.79
Net profit for the period	(10.68)	(34.65)	Loss narrowed	0.11	Turned loss
Attributable to shareholders of the company	(9.96)	(33.95)	Loss narrowed	(0.72)	Loss widened
EPS, basic (₹)	(0.53)	(2.03)	not comparable	(0.04)	Loss widened
Net margin (%)	-2.5	-8.8		0.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	191.44	181.91	+5.2%	272.60	−29.8%
Other income	3.69	1.78	+107.2%	8.94	−58.7%
Total income	195.13	183.69	+6.2%	281.53	−30.7%
Profit before tax	(16.38)	(17.60)	Loss narrowed	11.90	Turned loss
Net profit for the period	(10.68)	(13.68)	Loss narrowed	15.62	Turned loss
EPS, basic (₹)	(0.57)	(0.82)	not comparable	0.86	Turned loss
Net margin (%)	-5.6	-7.5		5.7

Consolidated

Filed with BSE: 08 Aug 2025, 17:51 IST
Board meeting: 08 Aug 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 08 Aug 2025, 17:51 IST
Board meeting: 08 Aug 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE